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The goal of equitable access to cadaveric organs 
was the guiding principle behind the development and 
implementation of the point system. This computerized 
allocation program originated in Pittsburgh (1), and was 
later adopted by the United Network for Organ Sharing 
(UNOS); more recently it has been modified (2). We 
have previously described our experience with the point 
system and emphasized the importance of immunosup-
pression as a factor in determining graft survival (3,4}. 
This report summarizes our 3.75-year experience with 
the point system for cadaveric kidney transplantation. 
As such, it serves as a benchmark of what can be 
obtained with CsA-based immunosuppressive 
protocols. Beginning in October 1989, FK 506 was 
used for immunosuppression after renal transplantation 
(5). and the results of that change will be evaluated in 
the coming year. 
METHODS 
Between January 1, 1986 and October 19, 1989. 
806 cadaveric renal transplantations were perlormed in 
741 patients at the rniver~ity of Pittsburgh (Pres-
byterian-University Hospital and Children's Hospital). 
An additional 20 kidneys were excluded from analysis 
because of concomitant transplantation with another 
organ (liver. heart. or pancreas); similarly excluded 
were 34 kidneys from living-related donors. Seven 
hundred and fifty kidneys went to 692 adults. whose 
mean age was 42.4±12.8 years. and 56 went to 49 
children. Four hundred and fifty-three (61%) of the 
recipients were male and 288 (39%) female. Six 
hundred and thirty-six (86%) of the reCipients were 
White. and 105 (14%) were Black. One hundred and 
fifty-two (21%) were diabetic, and 112 (15%) had a 
panel-reactive antibody (PRA) level greater than 40%. 
Seventy-eight (11%) of the recipients were older than 
60 years of age. 
Immunosuppression in 1986 and 1987 was based 
on CsA and prednisone; approximately one-third of the 
patients transplanted in 1987. and essentially all of the 
patients transplanted in 1988 and 1989, were also given 
azathioprine. OKT3 was used occasionally from the 
outset in selected sensitized patients or for steroid-
resistant rejection episodes (6). 
Pretransplant crossmatching was performed by the 
standard Iymphocytotoxic test with 2 washes, and the 
patients with positive crossmatches (20% killing of 
donor lymphocytes) using current sera were usually but 
not always precluded from transplantation. Pretreat-
ment of recipient sera with dithiothreitol (7) was not 
routinely performed. 
RESULTS 
Patient Survival 
One- and 2-year actuarial patient survival was 93% 
and 91% (Fig. 1). Fifty-nine (8%) patients have died 
between 1 day and 3.5 years after transplantation. The 
causes of death are noted in Table 1. Infections remain 
the most important cause of death, followed by car-
diovascular events. There may have been a slight 
trend toward decreased mortality in the last 1 or 2 
years. 
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Table 1. Causes of death after renal transplantation. 
Cause of Death Graft Functioning 
Infection 4 
Cardiovascular 7 
Gastrointestinal 1 
Respiratory 0 
-
Malianancy 1 
Technical 1 
Miscellaneous 3 
I (Ole, multiple organ failure, hyperkalemia, bleed after biopsy. subdural hematoma, suicide, 
Ii motor vehicle accident) 
Ii Unknown 0 
ij Total 17 (29%) 
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Figure 1. Patient survival after 
cadaveric renal transplantation. 
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Figure 2. Graft survival after 
cadaveric renal transplantation. 
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One- and 2-year actuarial graft 
survival was 74% and 68% (Fig. 2). 
Analysis of results by sex (Fig. 3) 
or race (Fig. 4) showed no effect of 
either variable. The irrelevance of 
recipient race to outcome has been 
noted previously (8). Adults and 
children had similar results (Fig. 5), 
as did patients receiving primary 
kidney transplants or retransplanta-
tions (Fig. 6). Analysis of graft sur-
vival on the basis of HLA antigen 
matches and mismatches was also 
performed. No discernible statisti-
cal effect was noted (Figs. 7 and 8). I Figure 3. Effect of recipient sex. 
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Figure 4. Effect of recipient 
race. 
Figure 5. Adult versus 
pediatric recipients . 
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Figure 6. Primary ~er-=sus 
retransplantation. 
Figure 7. Effect of +iLA 
matching. 
Figure 8. Effect:::;" HLA 
mismatching. 
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Patients older than 60 years of age 
had similar graft survival (Fig. 9) but 'M> GRAFT SURVIVAL 
worse patient survival (Fig. 10) than 
patients younger than 60 years of 
age. Patients with high levels of 0.8 
anti-HLA antibodies (PRA > 40%) -.. 
had slightly worse results than low 0.' • - - ... - • - -&- - - -
PRApatients (Fig. 11). 
Effect of 
Immunosuppression 
Protocol 
The largest effect noted was the 
influence of immunosuppressive 
protocols on graft survival. Three-
drug immunosuppression with CsA, 
azathioprine, and prednisone had 
consistently superior results when 
compared to immunosuppression 
with CsA and prednisone alone, 
with 80% 1-year graft survival 
(Figs. 12 and 13). This 10-15% im-
provement in graft survival has 
been a consistent finding in our 
patient population, a group well 
represented by older, sensitized, 
diabetic, andlor overweight 
patients. 
DISCUSSION 
The original intent of the point 
system was to design an allocation 
protocol that dId not consider age, 
sex, race, or significant medical 
problems. As such, it ran counter 
to the philosophical goal of 
transplanting the "best" potential 
recipients (9). Our results repre-
sent the longest experience with 
the original point system, which has 
since been modified to give less 
emphasis to waiting time and more 
to HLA matching. It will be interest-
ing to see whether the revised point 
system will in fact lead to greater 
matching in kidney transplantation 
and whether there will be any effect 
on graft survival; our own ex-
perience suggests that there will 
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Figure 9. Effect of age on graft survival. 
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Figure 10. Effect of age on patient survival. 
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Figure 11. Effect of panel-reactive antibody (PRA). 
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As an example. a patient of ours 
was transplanted in 1989 with a 3-
antigen match kidney that had been 
recovered locally. had been 
shipped out for a 6·antigen match 
recipient, and then was returned 
because of a positive cross match 
with the intended recipient. We 
were not informed that the kidney 
had been placed on a perfusion 
pump while it was away and that a 
tie had been placed around the 
renal artery to secure the perfusion 
catheter. When the kidney was 
returned to Pittsburgh and 
transplanted here, the artery 
promptly thrombosed because of 
intimal injury from the tie. The 
patient died after allograft nephrec-
tomy. The case is reported as a 
failure of an imperfectly matched 
kidney but was not recorded in the 
6-antigen match statistics, even 
though the attempt at organ sharing 
ultimately led to the graft failure. 
Other examples, equally florid or 
more subtle, could be cited. 
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p·0.0004 
30 38 42 
Figure 13. Effect of immunosuppressive protocol in primary and 
retransplantation. 
First, it demonstrates what can be 
expected with CsA'azathioprine-
based protocols using an equitable 
allocation policy which insures the 
systematic inclusion of high-risk 
recipients. Second. it can serve as 
an historical control in 2 ways; 1 to 
compare with different allocation 
protocols, and the other to compare 
not be any positive effect. Instead, the emphasis on 
matching can have unintended deleterious effects that 
will not necessarily be reported. 
with different immunosuppressive 
regimens. Although evaluation of the new immunosup-
pressive agent, FK 506, is planned with prospective 
randomized trials, this data base will be useful as an 
additional baseline for comparison. 
SUMMARY 
Eight hundred and sixty kidney transplants were 
performed at the University of Pittsburgh over a 3.75-
year period between January 1, 1986 and October 
19, 1989. Recipient selection was by means of a 
computerized point system designed to allocate or-
gans equitably. Ninety·three percent 1-year patient 
survival and 74% 1-year graft survival were obtained 
in the overall group; 80% 1-year graft survival was 
obtained in patients receiving immunosuppression 
with CsA, azathioprine, and prednisone. These data 
serve as a measure of what can be achieved with an 
equitably based allocation system and can serve as 
a basis of comparison with other allocation protocols 
or new immunosuppressive regimens. 
293 
REFFERENCES 
1. Starzl TE. Hakala T, Tzakis, et al. A muttifa::or.e>a. 
system for equitable selection of cadaveric '.cn€"ev 
recipients. JAMA 1987; 257:3,073. 
2. UNOS update, Vol 6, No.1, 1990. 
3. Shapiro R, Tzakis AG, Hakala TR. :: ~OK 
Cadaveric renal transplantation at the Unive:.!V " 0' 
Pittsburgh: A two and one half year expe-ennC€ 
with the point system. In: Terasaki PI, Ed. C;imc=a: 
Transplantation 1988. Los Angeles, UCLA -SSi.:>:J€ 
Typing Lab, 1989; 181. 
4. Shapiro R. Tzakis A, Hakala T, et al. Cacavew?~c 
renal transplantation under the American 2rg<:ian 
Allocation System. In: Bonomini, Scola- \1\.10. 
Stefoni S. et ai, Eds. Biotechnology in Re:a/ =~­
placement Therapy, Contrib Nephrol 3asee:. 
Karger, 1989; 70:30. 
ACKNOWLEDGMENTS 
We wish to thank the following people: 
Regina Fenton, R.N, Deborah Good, R.N. Jo<:>an 
Murray. R.N., Loraine Kaminski, R.N., Holly Wcocos. 
R.N., and Lisa Streb, R.N., for their invaluable ccrmt:'DtJ· 
tions to the care of the patients and the data colec:::on: 
Donna Ross for her untiring work in the prepamon . of 
the manuscript; Sandi Mitchell, MSIS. ":~annne 
Kowalski. and Kristine Smerdel for their heo ,vwTth 
the data analySIS; Robert W. Karausky. Tf""Y N. 
5. S::arz: TE, Fung J, Jordan M, et al. Kidney 
Ira-:sp;,antation under FK 506. JAMA. submitted. 
6. cKKg~ JJ. Demetris AJ, Porter KA, et al. Use of 
()o(T3 with cyclosporine and steroids for reversal 
c· aC_1e kidney and liver allograft rejection. 
fDKKepr:~n 1987; 46:19. 
7. I.ak, Y. Lau M, Terasaki PI. Successful 
t-a.,solants across T warm to M positive 
C"D:::ss~KatchesK Clin Transplant 1988; 2:81. 
8. S-.aptro R, Tzakis AG, Hakala TR, Lopatin WB, 
Steber AC, Starzl TE: Renal transplantation in 
b.ack recipients at the University of Pittsburgh. 
T-ar'1sp:ant Proc 1989; 21 :3921. 
9. F-yd OS. The selection of cadaver kidney 
recipients. JAMA 1988; 259:840. 
Trees Ph.D., and Richard James for their help in 
fashlcnmg t!)e slides, figures and tables. 
Sooported by Research Grants from the Veterans 
Admlr"1straton and Project Grant No. DK 29961 from 
the Na:lor.a: Institutes of Health, Bethesda, Maryland. 
Reorrnt requests should be sent to Thomas E. Starzl, 
M.D .. ::>h.D. Department of Surgery, 3601 Fifth Avenue, 
Falk Cil!itC SC, Pittsburgh, Pennsylvania 15213. 
